Women's Health Across the Nation - Endocrine Lab

描述（由申请人提供）：这一年的竞争性续期是 作为一套九个组成部分的申请之一提交（包括七个 临床研究中心、协调中心和中心内分泌实验室） 为了增加目前五年期延长（SWAN II）的最后一年， 九个最初资助的申请，以响应RFA AG-94-002，“更年期” 老年妇女的健康" 这次延期的目的是完成第六次年度随访， 临床研究中心约有2470名女性， 每天收集大约550名妇女的尿液。每个数据 收集活动需要两年时间才能完成。天鹅II 申请包括完成访视02至访视00和访视01的资金 数据收集，进行访视03、04和05数据收集， 最后一年花在分析上。初步数据现已从访问 00-03表明，这项重要研究的最初和持续目标 无法通过目前供资的五年后续行动来解决 观察，因为更年期过渡的数量将是不够的。 预测表明，将需要9年的后续行动。桥接 需要资金（此补充申请），以便在 完成访视06的队列随访可以关闭。竞争性的更新 五年（SWAN III）必须基于持续的数据收集， 队列保留率、随访完整性和经认证的工作人员可用性， 放心因此，有必要获得这笔补充资金， SWAN II中计划用于关闭和数据分析的时间。 为了评估中年妇女的内分泌变化，密歇根大学？S 中央配体分析卫星服务（CLASS）实验室将继续 通过使用最先进的自动化检测技术， 生殖轴激素（LH、FSH、E2、P和T），衰老的肾上腺标志物 （DHEAS），其他内分泌标志物（TSH，SHBG）和新的卵巢标志物， 有可能让我们从性别上定义更年期 和绝经后更精确（雌激素B，雌酮）。为了 为了继续支持每日激素研究，CLASS将利用敏感的 以及LH、FSH和主要尿代谢产物的特异性尿分析 雌二醇和孕酮、雌酮结合物和孕激素 葡萄糖醛酸苷。 为了评估中年妇女的内分泌变化，密歇根大学？S 中央配体分析卫星服务（CLASS）实验室将继续 通过使用最先进的自动化检测技术， 生殖轴激素（LH、FSH、E2、P和T），衰老的肾上腺标志物 （DHEAS），其他内分泌标志物（TSH，SHBG）和新的卵巢标志物， 有可能让我们从性别上定义更年期 和绝经后更精确（雌激素B，雌酮）。为了 为了继续支持每日激素研究，CLASS将利用敏感的 以及LH、FSH和主要尿代谢产物的特异性尿分析 雌二醇和孕酮、雌酮结合物和孕激素 葡萄糖醛酸苷。

DESCRIPTION (provided by applicant): This one year competing renewal is submitted as one of a set of nine component applications (including seven clinic sites, the Coordinating Center and a Central Endocrinology Laboratory) to augment the last year of the current five-year renewal (SWAN II) of the nine originally funded applications in response to RFA AG-94-002, "Menopause and Health in Aging Women." The purpose of this renewal is to complete a sixth annual follow-up visit on approximately 2470 women across clinical sites and a final annual cycle of daily urine collections on approximately 550 women. Each of these data collection activities requires a two-year period for completion. The SWAN II application included funding to finish Visit 02 to the Visit 00 and Visit 01 data collections, to undertake Visits 03, 04 and 05 data collections and to spend the final year on analyses. Preliminary data now available from Visits 00-03 indicate that the original and continuing aims of this important study cannot be addressed with the currently funded five years of follow-up observation as the number of menopause transitions will be insufficient. Projections indicate that nine years of follow up will be required. Bridging funding (this supplement application) is needed so that a one year gap in cohort follow-up to complete a Visit 06 can be closed. A competing renewal for five years (SWAN III) must be predicated on continuing data collection so that cohort retention, follow-up integrity and certified staff availability is assured. Hence there is a need to obtain this supplemental funding to bridge the time in the SWAN II that was planned for closeout and data analysis. To assess endocrine changes in midlife women, the University of Michigan?s Central Ligand Assay Satellite Services (CLASS) laboratory will continue to support SWAN by using state-of-the-science, automated assays for all the major reproductive axis hormones (LH, FSH, E2, P, and T), adrenal markers of aging (DHEAS), other endocrine markers (TSH, SHBG) and new ovarian markers which have the potential to allow us to hormonally define the menopausal transition and the postmenopause with greater precision (inhibin B, estrone). In order to continue to support the Daily Hormone Study, CLASS will utilize sensitive and specific urinary assays for LH, FSH and the principal urinary metabolites of estradiol and progesterone, estrone conjugates and pregnanediol glucuronide, respectively. To assess endocrine changes in midlife women, the University of Michigan?s Central Ligand Assay Satellite Services (CLASS) laboratory will continue to support SWAN by using state-of-the-science, automated assays for all the major reproductive axis hormones (LH, FSH, E2, P, and T), adrenal markers of aging (DHEAS), other endocrine markers (TSH, SHBG) and new ovarian markers which have the potential to allow us to hormonally define the menopausal transition and the postmenopause with greater precision (inhibin B, estrone). In order to continue to support the Daily Hormone Study, CLASS will utilize sensitive and specific urinary assays for LH, FSH and the principal urinary metabolites of estradiol and progesterone, estrone conjugates and pregnanediol glucuronide, respectively.